Castle Biosciences/$CSTL
1D1W1MYTD1Y5YMAX
About Castle Biosciences
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
- Ticker
- $CSTL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,002
- Headquarters
- Friendswood, United States
- Website
- castlebiosciences.com
CSTL Metrics
BasicAdvanced
$1B
-
-$0.65
0.97
-
Price and volume
Market cap
$1B
Beta
0.97
52-week high
$44.28
52-week low
$17.72
Average daily volume
471K
Financial strength
Current ratio
6.036
Quick ratio
5.602
Long term debt to equity
6.875
Total debt to equity
7.797
Interest coverage (TTM)
-32.02%
Profitability
EBITDA (TTM)
-16.516
Gross margin (TTM)
77.26%
Net profit margin (TTM)
-5.43%
Operating margin (TTM)
-3.36%
Effective tax rate (TTM)
-1.10%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-1.36%
Return on equity (TTM)
-4.20%
Valuation
Price to revenue (TTM)
2.846
Price to book
2.22
Price to tangible book (TTM)
2.79
Price to free cash flow (TTM)
-2,079.388
Free cash flow yield (TTM)
-0.05%
Free cash flow per share (TTM)
-0.016
Growth
Revenue change (TTM)
3.18%
Earnings per share change (TTM)
96.09%
3-year revenue growth (CAGR)
28.72%
3-year earnings per share growth (CAGR)
-42.00%
What the Analysts think about CSTL
Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.
CSTL Financial Performance
Revenues and expenses
CSTL Earnings Performance
Company profitability
CSTL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.